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In this review, we discuss recent work by the ENIGMA Consortium (http://enigma.ini.usc.edu) – a global alliance
of over 500 scientists spread across 200 institutions in 35 countries collectively analyzing brain imaging, clinical,
and genetic data. Initially formed to detect genetic inﬂuences on brain measures, ENIGMA has grown to over 30
working groups studying 12 major brain diseases by pooling and comparing brain data. In some of the largest
neuroimaging studies to date – of schizophrenia and major depression – ENIGMA has found replicable disease
effects on the brain that are consistent worldwide, as well as factors that modulate disease effects. In partnership
with other consortia including ADNI, CHARGE, IMAGEN and others1, ENIGMA's genomic screens – now number-
ing over 30,000 MRI scans – have revealed at least 8 genetic loci that affect brain volumes. Downstream of gene
ﬁndings, ENIGMA has revealed how these individual variants – and genetic variants in general –may affect both
the brain and risk for a range of diseases. The ENIGMA consortium is discovering factors that consistently affect
brain structure and function thatwill serve as future predictors linking individual brain scans and genomic data. It
is generating vast pools of normative data on brain measures – from tens of thousands of people – that may help
detect deviations from normal development or aging in speciﬁc groups of subjects. We discuss challenges and
opportunities in applying these predictors to individual subjects and new cohorts, as well as lessons we have
learned in ENIGMA's efforts so far.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Here we provide an update on the progress of the ENIGMA consor-
tium, a global alliance of over 500 scientists from over 200 institutions
in 35 countries to study brain imaging data worldwide, discovering
factors that modulate brain structure, integrity, connectivity, and
patterns of brain differences in major brain diseases. Founded in 2009,
ENIGMA's initial aims were to perform genome-wide analyses to iden-
tify common variants in the genome that are reliably associated with
1 Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative (http://www.adni-
info.org); CHARGE, the Cohorts for Heart and Aging Research in Genomic Epidemiology
Consortium (http://www.chargeconsortium.com); IMAGEN, IMAging GENetics Consor-
tium (http://www.imagen-europe.com).
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normal variability in brain structure. Since the initial effort discovered
consistent effects worldwide of genetic variants that explained less
than 1% of the variance in brain measures (Stein et al., 2015; Hibar
and the CHARGE and ENIGMA2 Consortia, submitted for publication;
Hibar et al., 2015a,b, in press), over 500 scientists have joined ENIGMA.
ENIGMA is now (as of October 2015) a worldwide consortium, orga-
nized into over 30 working groups, studying major brain diseases (de-
tailed at http://enigma.ini.usc.edu). The work in ENIGMA is divided
into projects on (1) genetics, screening genomic data for predictors of
individual variations in brain structure, function, and connectivity;
(2) disease, screening brain measures to identify patterns of differences
in the major brain diseases and factors that affect them; and
(3) methods development. New “Big Data” methods are being devel-
oped and implemented around the world to perform genetic analysis
of high-dimensional features that arise in neuroimaging — such as
brain networks or “connectomes” (Sporns et al., 2005), 3D or 4D maps
of brain changes over time, and more complex imaging data from
functional MRI and EEG/MEG.
For this issue of NeuroImagewe review thework ENIGMA has done,
and how it relates to making individual predictions to support the
emerging discipline of precision medicine—where personalized medi-
cal decisions are made considering an individual's genetic make-up,
other risk factors, and the large body of scientiﬁc knowledge detailing
genotype-phenotype relationships. ENIGMA's genetic and disease-
related studies are discovering new factors that affect the brain
throughout life, how the diseased brain differs from the healthy brain,
and how patterns of brain measures differ from one disease to another.
The potential to use machine learning methods in this context is vast,
and we point to future opportunities and challenges, and what we
have learned already about how individual genetic variants and
diseases affect the brain.
One major thrust of ENIGMA's work is genomics, so we ﬁrst review
studies that discovered individual loci in the genome that are linked to
variations in brain structure (Stein et al., 2012; Hibar and the CHARGE
and ENIGMA2 Consortia, submitted for publication; Hibar et al., 2015a,
b, in press). The effect of these common genetic variants tends to be
small, but the aggregate effect of thousands of them accounts for a sub-
stantial proportion of the variance in brain measures (Toro et al., 2015;
Ge et al., 2015; Chen et al., 2015). The relevant genes can be difﬁcult to
discover in individual cohorts, but they can be detected by meta-
analyzing data across multiple sites. We discuss multivariate and ma-
chine learning methods needed to combine some of these predictors
in more powerful models that can make valuable predictions about in-
dividuals, such as predicting deviations from normal lifetime aging,
risk for mental illness, or recovery from trauma.
Reproducibility
There have been numerous recent surprises regarding the nature of
gene effects on the brain, including surprisingly poor reproducibility of
candidate gene effects on imaging measures and risk for mental illness,
and the very large sample sizes needed to reliably detect any genetic
associations at all. There have also been dramatic claims of poor
reproducibility of ﬁndings in genetics, neuroimaging, and neuroscience
studies in general (Button et al., 2013; Ioannidis, 2014; Ioannidis et al.,
2014). Meta-analyses, such as those conducted by ENIGMA, have been
proposed as a way to screen for false positive ﬁndings. If claims of “sig-
niﬁcance chasing” and “ﬁshing” in neuroscience studies are true
(Ioannidis, 2014), then predictive models based on them should fail
more often than models based on meta-analyzed studies of large num-
bers of independent cohorts, analyzed in a harmonized way (Ware and
Munafò, 2015). ENIGMA is dedicated to replication, and a number of ini-
tiatives are underway to develop methods to replicate imaging geno-
mics ﬁndings.
We discuss factors that affect reproducibility of models that predict
speciﬁc gene effects on the brain, including technical factors of image
acquisition and analysis. Low effect sizes for individual predictors
make genetic effects hard to detect, so meta-analysis is valuable in
demonstrating effects that no single cohort can detect on its own.
Clearly, if we build a model to classify a person into a certain diagnostic
group, based on a set of predictors, we also need to know how to decide
if we havemeasured the predictors well enough, or if the context where
the model was ﬁtted is similar enough to the current situation for the
prediction to make sense and be accurate. Apart from the choice of
predictive model and predictors, there are many other reasons why
imaging or genetic models of diagnosis or prognosis may generalize
poorly or not at all, depending on the context. Factors that affect
model prediction will include age and environment, and the demo-
graphic history of the populations sampled; these may affect whether
or not a predictor is relevant to a new cohort or an individual. In the
ENIGMA studies below, we point to examples in which predictors
in the genome and image would be valuable in making individual
predictions about brain volume or about a person's diagnosis, but only
in certain contexts, such as in certain parts of the lifespan, or only
after considering certain confounds or variables that are known to
drive brain differences (duration of medication and duration of illness
are often confounded, and modeling each effect independently may
produce paradoxical conclusions, e.g., that medication is bad for the
brain). Individual predictive models are likely to become increasingly
nuanced, as we ﬁnd out more about how predictors interact and
contexts where different models work best.
In the course of ENIGMA's efforts, a vast quantity of normative data
has been gathered and analyzed fromdifferent countries and continents
of the world, allowing us to make some inferences about the normal
trajectory of brain development and aging (ENIGMA-Lifespan; Dima
et al., 2015). We discuss the challenges and opportunities in using
models based on these data to make assertions about individual and
group deviations from normal, or to generate cohort, or national
norms, if they exist and if their value outweighs the costs of generating
them.
We also discuss several concepts that have increased the power of
ENIGMA to ﬁnd factors with very small effects on the brain, including
how we assess their generality and extensibility to new cohorts.
ENIGMA's Genetic Studies
By December 2009, many researchers worldwide had collected
genome-wide genotyping data from cohorts of subjects for whom
brain imaging information such as anatomical MRI was available.
It had long been presumed that genetic and environmental factors,
and the complex interactions among them, play a role in shaping
brain structure. Decades of work in behavioral and medical genetics
had convincingly shown that many of the major brain diseases – from
Alzheimer's and Parkinson's disease to psychiatric illnesses such as
schizophrenia and major depression – had a strong additive genetic
component. Similar genetic risks exist for neurodevelopmental disor-
ders such as autism. Even so, studies of identical twins who share the
same genome show that genetic factors do not fully account for disease
risk, and discordant twin pairs provide valuable information about the
impact of environmental and epigenetic factors on disease (Munn
et al., 2007). Furthermore, many common disorders are likely to reﬂect
a constellation of modest gene differences acting in concert, which
smaller individual studies are unlikely to ﬁnd. Instead, larger studies
that capture heterogeneity have begun to unravel the inﬂuence of
multiple ‘low level’ minor but important gene differences on disease
expression (Lopez et al., 2015).
As high-throughput genotypingmethods became available, genome-
wide association studies (GWASs) began to reveal speciﬁc sources of
risk in the genome for several major brain diseases (Fig. 1). To fully
appreciate this kind of study, we need to understand that much of the
genome is invariant between humans (Rosenberg et al., 2002). Many
kinds of individual genetic variations – common or rare – can occur,
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including polymorphisms, insertions and deletions of genetic material,
loss or retention of homozygosity (LOH/ROH), or copy number
variations (CNVs) — where the number of copies of pieces of genomic
material differs from the normal two alleles in some individuals but
not others. Polymorphisms are a common marker of individual differ-
ences, where a single nucleotide polymorphism (SNP) is essentially a
“single-letter” change in the genome: a change in a single base pair
between individuals.
Some genomic changes interfere with the viability of the organism,
leading to very low frequencies in the population. Others remain and
some have a moderate or severe impact on a person's health, or their
risk for disease. For example, a common variant (present in 1 in 100 in
the general population) in the HFE gene impairs a person's ability to
metabolize iron. Excessive iron levels can then accumulate in bodily
organs, which can cause liver and kidney failure. Multiple deletions in
the 22q region of the genome provide another example. Individuals
with these deletions have a characteristic neurodevelopmental proﬁle
associated with mild to severe abnormalities in the face, brain, and
heart, and are at heightened risk for schizophrenia and autism. 22q
deletions occur frequently de novo, so they do not really remain in the
Fig. 1. Recent genome-wide association studies (GWAS) of brain disorders and brain structure. Part A shows the Manhattan plot from a 2014 Naturemeta-analysis conducted by the
Psychiatric Genomics Consortium. The genetic variants are presented on the x-axis, and the height of the dots shows the strength of association between each genetic variant and
schizophrenia. A negative log p-value scale is used: higher points denote stronger associations. The group identiﬁed 108 schizophrenia-associated genetic loci in a sample of 34,241
cases and 45,604 controls (red line = genome-wide signiﬁcance level, conventionally set at p = 5x10−8; green SNPs = polymorphisms in linkage disequilibrium with index SNPs
(diamonds), which indicate independent genome-wide signiﬁcant signals). Part B 26 loci signiﬁcantly associated with risk of Parkinson's Disease (Nalls et al., 2015), in 13,708 cases
and 95,282 controls (red SNPs = genome-wide signiﬁcant signals). Part C 19 loci signiﬁcantly associated with risk of AD, in a sample of 17,008 cases and 37,154 controls (Lambert
et al., Nature Genetics, 2013; genes identiﬁed by previous GWAS are shown in black; newly associated genes in red; red diamonds indicate SNPs with the smallest overall p-values in
the analysis). Part D shows genome-wide associations for eight subcortical structures, conducted by the ENIGMA consortium in 30,717 individuals from 50 cohorts worldwide (Hibar
et al., Nature, 2015). This study identiﬁed ﬁve novel genetic variants associated with differences in the volumes of the putamen and caudate nucleus and stronger evidence for three
previously established inﬂuences on hippocampal volume (see Stein et al., Nature Genetics, 2012) and intracranial volume (see Ikram et al., Nature Genetics, 2012). Each Manhattan
plot in Part D is color-coded to match its corresponding subcortical structure, shown in the middle row. The gray dotted line represents genome-wide signiﬁcance at the standard p =
5x10−8; the red dotted line shows a multiple-comparison corrected threshold of p = 7.1 x 10−9. [Images are reproduced here with permission from MacMillan Publishers Ltd (Nature
Genetics, 2012 & 2013; Nature, 2014 & 2015) and with permission from the corresponding authors.]
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population; rather 22q is a vulnerable spot in the genome for mutation.
Even so, 22q deletion syndrome – and other neurogenetic disorders
such as Fragile X, Williams syndrome, and Turner syndrome – have
often been studied to help identify potential mechanisms that may
contribute to more prevalent psychiatric conditions. ENIGMA's 22q
working group has been set up to understand brain differences associat-
edwith deletions at this locus, and how they relate to those found using
the same analysis protocols in ENIGMA-Schizophrenia and ENIGMA-
Autism.
Genetic risk for many major psychiatric illnesses is thought to
be mediated in part by common genetic variants that have persisted
in humanpopulations for thousands of years. Inmany cases, the adverse
effects of disease risk genes – such as the Alzheimer's risk gene, APOE –
are not apparent until later in life (Hibar and the CHARGE and ENIGMA2
Consortia, submitted for publication; Hibar et al., 2015a,b, in press). Be-
cause of this, the variants tend to be preserved in the gene pool and con-
tinue to drive disease risk worldwide.
Geneticists continue to debate the relative contribution of common
versus rare genetic variants to risk for various diseases, but a recent
large-scale screen of schizophrenia patient cohorts worldwide
implicated over 100 genetic loci in risk for the disease (Ripke et al.,
2014; Fig. 1). This highly successful study pointed to several genes
in the dopamine neurotransmission pathway that had long been impli-
cated in schizophrenia and its treatment — for example, a functional
polymorphism in the DRD2 promoter region, which modulates levels
of gene expression, and affects antipsychotic drug efﬁcacy (Zhang and
Malhotra, 2013). This same genomic screen pointed to other unexpect-
ed genetic variants in immune system pathways that offer tantalizing
new leads about disease mechanisms, and the role of modiﬁable factors
in eventually treating or averting the illness. Similar efforts in bipolar
illness, major depression, and ADHD uncovered genes driving risk for
these disorders that overlapped to some extent with those for schizo-
phrenia and with each other (Cross Disorders Working Group of the
Psychiatric Genomics Consortium, 2013). Members of the ENIGMA
Consortium have recently demonstrated the usefulness of polygenic
risk scores for schizophrenia (based on the 108 loci shown in Fig. 1A)
in revealing an association between early cannabis use and brain matu-
ration during adolescence — replicated in three samples (French et al.,
2015).
Many successful genomic screens involve over 100,000 individuals.
For example, the most recent GWAS of height, educational attainment,
and body mass index (BMI) identiﬁed 56 novel BMI-associated loci in
a sample of up to 339,224 individuals (Wood et al., 2014; Locke et al.,
2015). Similarly, the Psychiatric Genomics Consortium's discovery of
genetic loci implicated in schizophrenia risk took a ‘quantum leap’
once the sample sizes exceeded 75,000 (Ripke et al., 2014), after less
successful searches in smaller samples. Several factors may contribute
towards this need for large sample sizes in genome-wide association.
First, there are biological variation and ascertainment differences
among cohorts. A person diagnosed with a speciﬁc illness may have
other co-morbid illnesses, and diagnostic criteria may vary somewhat
worldwide in terms of who is included in the groups of patients and
controls.
However, the main reason GWAS needs large samples is power: a
genome-wide association analysis comprises approximately a million
independent tests, so a threshold of p b 5 × 10−8 is employed to mini-
mize false positives. Early GWAS estimated their required sample sizes
based on published effect sizes of candidate genes that have since
been shown to be greatly overestimated. Although the genetic architec-
ture of each trait is unique, for most complex traits the effect sizes of
individual SNPs are typically less than half a percent (Franke et al., in
press). Thus, it follows from power analyses that GWAS and GWAS
meta-analyses typically require data from tens of thousands of
individuals.
In the imaging ﬁeld, initial studies also attempted genome-wide
screens of brain imaging measures, such as brain size (Paus et al.,
2012), the volume of the temporal lobes on MRI (Stein et al., 2010a,b),
in cohorts of around 800 subjects (see Medland et al., 2014, for a
review). This type of analysis became feasible as large cohort studies,
such as the Alzheimer's Disease Neuroimaging Initiative (Jack et al.,
2015), started to put their images and genomic data online. In line
with accepted practice in genetics, it is customary to require replication
of such genetic effects in independent cohorts.
While some effects appeared to replicate, most did not as the studies
were underpowered, and it was unclear whether cohort factors, biolog-
ical differences, or technical factors were to blame.
Endophenotype Theory and Power
As the ﬁeld of imaging genetics grew, some researchers hoped that
imaging might offer a more efﬁcient approach to discover genes
involved in mental illness. The reason for this optimism was based on
the observation that many brain measures are consistently reported as
affected in psychiatric cohort studies (see later, under ENIGMA Disease
Studies), so they could maybe serve as quantitative traits, or markers,
correlated with the illness.
There was also some hope that the biological signals in images –
measures of neurotransmitters, receptors or metabolite levels, blood
ﬂow, the volume of specialized brain areas such as the hippocampus,
or its chemical content – might be inﬂuenced by genetic variants
because of their proximity to primary gene action. Likewise, it was
argued that brain-derived measures may have a simpler genetic
architecture – perhaps with fewer individual genes or pathways
inﬂuencing them – compared to the multitude of factors driving a
person's overall risk for developing a disease (Saykin et al., 2015).
Brainmeasuresmay also offer amore precise or reproducible diagnostic
scale. Potkin et al. (2009) noted that GWAS can be more efﬁcient when
researchers analyze continuousmeasures (such as brain volumes) rath-
er than binary traits, such as diagnosis, which may also disguise com-
plexities such as co-morbidity, etc.
This endophenotype theory2 led to conﬁdence that genome-
wide screening of brain measures would yield “hits” – genetic loci
consistently associated with brain measures – relatively efﬁciently
and, some believed, in much smaller samples. Several countervailing
arguments should also be considered. The genetics of brain traits may
reveal common pathways involved in a number of mental illnesses,
but one loses some speciﬁcity whenmoving from a psychiatric disorder
to brain measures — different disorders may have very similar brain
abnormalities. For this reason, ENIGMA's Disease Working groups
have analyzed tens of thousands of brain scans to see which measures
best distinguish patients from controls, across a range of 12 diseases,
with a view to understanding similarities and differences. Collecting
brain imaging data is more expensive than diagnostic testing. Also,
genes that affect brain measures may be of less interest to a patient or
physician unless they are also connected to disease risk or prognosis.
In ENIGMA, however, the costs of collecting the imaging data had
already been incurred, making the feasibility of a large-scale analysis
the main consideration. Others voiced a muted optimism: Munafò and
Flint (2014) noted that effect sizes for gene effects on neuroimaging
data were not likely to be any greater than for any other trait, but the
value in studying them came from the ability of brain measures to
help understandmechanisms that might underlie associations between
genes and more conventional traits (see also Flint et al., 2014). Yet,
the potential to ﬁnd genetic factors that jointly inﬂuence risk for mental
2 The term “endophenotype” was coined by John and Lewis (1966); in psychiatric ge-
netics, it is used to denote a biomarker that fulﬁlls several criteria (Gottesman and Gould,
2003; Glahn et al., 2014), including heritability, reproducible measurement, segregation
with illness in families and in the general population, and state-independence — it must
remain stable when a patient's illness is active or in remission. Others used the term “in-
termediate phenotype” for the brain measures studied in imaging genetics, as the
endophenotype refers to the characteristics that are shared by both patients and their un-
affected ﬁrst-degree family members.
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illness and a neuroimaging trait could dramatically improve statistical
power and provide an important link between the genome and the
behavioral symptoms used to diagnose psychiatric and neurological
illnesses (Glahn et al., 2014).
In ENIGMA's ﬁrst paper in Nature Genetics, Stein and 158 authors
(2012), including 4 existing consortia (SYS, EPIGEN, ADNI, and
IMAGEN3), meta-analyzed GWAS data from cohorts worldwide and
found genetic loci consistently associated with the size of the
human hippocampus and total intracranial volume. Notably, in a
partnership with another consortium, CHARGE (Bis et al., 2012),
the top “hits” – the genetic variants with greatest effect sizes –
were anonymously exchanged and found to be the same, supporting
the replicability of the ﬁndings in completely independently de-
signed efforts.
In a follow-up study in a larger sample (N = 21,151 individuals;
Hibar and the CHARGE and ENIGMA2 Consortia, submitted for pub-
lication; called “ENIGMA2”), eight genetic loci were discovered that
were reliably associated with the size (volume) of several subcorti-
cal structures, including the putamen, caudate, and pallidum. With
the increased sample size, earlier ﬁndings regarding the hippocam-
pus and intracranial volume were replicated and reinforced; new
genetic loci were also discovered. Several of the SNPs implicated
lie within or close to genes involved in cell migration, axon guid-
ance, or apoptosis — all cellular processes likely to lead to observ-
able differences in the size of cellular nuclei in the brain. Parallel
work in mice by the Williams lab in Memphis began to study
mouse homologs of these variants (Ashbrook et al., 2014); recent
data suggest that variation of the top putamen gene, KTN1, can pre-
dict putamen volume and cell counts in outbred mice (R. Williams,
pers. commun.).
Several lessons were learned from the ﬁrst two ENIGMA genetic
studies, in addition to a third pair of papers currently in submission,
involving an even larger sample (N N 31,000; Hibar and the CHARGE
and ENIGMA2 Consortia, submitted for publication; Hibar et al., 2015a,
b, in press; Adams and the CHARGE and ENIGMA2 Consortia,
submitted for publication). First, throughmeta-analyses, it was possible
to detect factors (here, SNPs) that accounted for less than 1% of the var-
iance in brain measures. This was despite the fact that the participating
studies were designed with different goals in mind, and many used
scanners of different ﬁeld strengths, processed by researchers who
had not all met, and communicated through email and teleconference
calls.
Much of the consistency in brain measures capitalized on the
ongoing reﬁnement of standardized protocols for analyzing im-
ages and genomes; in turn, those protocols relied on decades of
work by developers of widely used and extensively tested analysis
packages such as FreeSurfer (Dale and Sereno, 1993; Fischl, 2012),
and FSL (Jenkinson et al., 2012). The supplement of the ﬁrst
ENIGMA paper (Stein et al., 2012) contained 104 pages of ancillary
tests supporting the validity and reliability of the data, including
tests comparing different imaging software for brain volume
quantiﬁcation.
On the genomic side, the ability to compare genomic data in a
common reference frame depended on the availability of the HapMap3
(The International HapMap3 Consortium, 2010) and later the 1000
Genomes reference datasets (Genomes Project C et al., 2010). These
reference panels are continually updated and reﬁned, and allow
genotyping data collected with one kind of genotyping array (“chip”)
to be imputed to match data collected using others, and pooled in the
same overall study.
A second issue is whether these ﬁndings could have been detected
more efﬁciently using only some of the samples. In a sense, this is a
“meta-question” — how might the study have been designed more
efﬁciently after seeing the results?
As in any meta-analysis, the weight assigned to each cohort in the
ﬁnal statistics can be made to depend on its total sample size, or on
the standard error of the regression coefﬁcients (which is in fact
what ENIGMA does). As such, it is not vital for every cohort to reject
the null hypothesis on its own. In fact, any cohort study, however
small, can partner with other sites to contribute to the discovery of
effects that it cannot detect alone. In ENIGMA1 (Stein et al., 2012),
only 5 of the 21 cohort studies were able to detect the effect of the
SNPs on the brain in their cohort alone, at the nominal signiﬁcance
level of p = 0.05. By the time of ENIGMA2, 20 of the 38 Caucasian
European (CEU) cohort studies could detect the effects of the top
SNP. Even so, the aggregate support of the discovery and replication
samples was crucial to making sure the effects were credible and un-
likely to be false positives.
Relevance to Disease Risk
The quest to identify genetic variants associated with brain mea-
sures is partly motivated by ﬁnding variants that affect our individual
risk for disease. Any modulators of health outcomes in populations
may have a vast impact on society, even if they are not themain factors
explaining risk for any one individual. As well as affecting risk for dis-
ease, genetic differences may also affect symptom severity, treatment
response, and prognosis.
As such, several clinical trials for Alzheimer's disease drugs already
stratify their cohorts by APOE genotype — a major risk gene for AD
that may have a bearing on treatment response as well as disease risk
(see Riedel et al., submitted for publication, for a review of APOE effects,
which are remarkably complex). At the time of writing, several manu-
scripts are under review addressing the overlap between ENIGMA's
genomic ﬁndings and accepted or emerging markers of disease risk
(Hibar and the CHARGE and ENIGMA2 Consortia, submitted for publica-
tion; Hibar et al., 2015a,b, in press; Adams and the CHARGE and ENIG-
MA2 Consortia, submitted for publication; Franke et al., in press). Here
we simply review their overall design. Some initial reports have ap-
peared in abstract form, relating brain-related SNPs to risk for
Parkinson's disease (Hibar and the CHARGE and ENIGMA2 Consortia,
submitted for publication; Hibar et al., 2015a,b, in press), obsessive
compulsive disorder (Hibar and the CHARGE and ENIGMA2 Consortia,
submitted for publication; Hibar et al., 2015a,b, in press), schizophrenia
(Stein et al., 2015; Franke et al., in press), andmultiple sclerosis (Rinker
et al., submitted for publication). An initial negative report has appeared
for epilepsy (Whelan et al., 2015). Even so, given the low fraction of her-
itability explained by the SNPs discovered, the studies so far are widely
accepted as underpowered.
One method to assess an individual's relative risk for disease, based
on genome-wide genotyping data, involves computing a polygenic
risk score (PRS) for each individual. In Alzheimer's disease, for example,
carrying one copy of the APOE4 genotype boosts lifetime risk for AD by a
factor of 3, and carrying two copies may boost risk by 15 times. These
odds ratios are not constant across human populations and even vary
by ethnicity, or circumstances, so some caution is needed when extrap-
olating them to new data; but as AD GWAS data accumulate, over 20
common genetic variants have been found to affect AD risk — 3 of
them, in the genes CLU, PICALM, and CR1, appear to be associated with
a difference in disease risk of over 10% per allele. If an individual's
genotype is known for these loci, it is possible to create a polygenic
risk score in a number of different ways, depending on whether the
goal is to predict diagnosis, outcome, or brain measures. The simplest
approach is to count risk loci, although that clearly ignores the vastly
different odds ratios from each locus. It is more common to weight the
loci based on their odds ratio for disease, or by their regression
3 Abbreviations: SYS, Saguenay Youth Study, http://www.saguenay-youth-study.org;
EPIGEN, The Epilepsy Genetics (EPIGEN) Consortium (Cavalleri et al., 2007); ADNI,
Alzheimer's Disease Neuroimaging Initiative (http://www.adni-info.org); IMAGEN, IMAg-
ing GENetics Consortium (http://www.imagen-europe.com).
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coefﬁcients. APOE4, for example, is just a single genotype that might
contribute to calculation of a polygenic risk score together with other
risk loci. As shown by the PGC analyses, the predictive accuracy of PRS
scores increases as the number of variants included increases. Calcula-
tion of these scores does not need to be restricted to genome-wide sig-
niﬁcant loci.
Recent efforts to predict disease status based on polygenic risk
scores have had varied success, but the reasons are quite well under-
stood. First, for the most prevalent neurological or psychiatric dis-
eases, we do not yet have a set of common variants that account for
more than a small fraction of disease risk (except for APOE4, where
a single copy may triple a person's risk for AD, other factors being
equal). In AD, there are rare mutations in genes related to AD pathol-
ogy – such as presenilin and APP – that invariably produce early-
onset AD. Carriers of these genetic variants are the targets of major
neuroimaging initiatives (Benzinger et al., 2013). A very important
aspect of this – relevant to the ﬁeld of personalized medicine – is
that the person's genotype in conjunction with amyloid imaging
can accurately predict the age of onset for the disease and the symp-
toms (Benzinger et al., 2013).
Another cause for optimism is the efforts of the Psychiatric Genomics
Consortium (PGC). When the PGC Schizophrenia Working Group
increased their sample size to 36,989 cases and113,075 controls, they dis-
covered over 100 loci associated with risk for schizophrenia, suggesting
that other GWAS may experience similar boosts, depending on where
they are in the arc of discovery. The rate of success of these efforts, and
yield on the efforts invested, also depends on the polygenicity of each
disease, and the distribution of risk loci across the genome. Holland
et al. (submitted for publication) used recent data from the ENIGMA
study and the PGC to estimate what sample sizes are needed for a
GWAS to discover enough SNPs to account for, say 50% or 80% of the
chip-based heritability, i.e., the amount of the population variance
predictable from genotyped SNPs. They argued that some traits are
more polygenic than others, and that, relative to some brain measures,
GWAS studies of schizophrenia and major depressive disorder may
require much larger sample sizes to discover enough SNPs to account
for high levels of the chip-based heritability. If that is true, then imaging
genetics may bewell on the way to a signiﬁcantly higher rate of discov-
ery, and a more complete understanding of common variants driving
individual differences in brain measures.
Howmuch individual variance is explainable by GWAS and common genetic
variants?
In recent years, a number of powerful methods emerged to estimate
what fraction of the population variance in a trait could be predicted, in
principle, from all the SNPs on the genotyping chip, even if the exact
genes and SNPs were not yet known.4 Predictions can be made from
the full set of association statistics: models (linear or Gaussian) are
ﬁrst ﬁtted to the observed effect sizes of all the SNPs, even if most SNP
effects fail to reach the accepted standard for genome-wide signiﬁcance.
In much the same way as FDR (the false discovery rate method) is used
in imaging to conﬁrm evidence for a distributed signal — spread out
across the brain, the overall effect of genome-wide SNPs on a trait can
be estimated without having to pinpoint which exact regions — of the
image or the genome— contribute unequivocally to the effect.
Hibar et al. (2015) used genome-wide summary statistics to esti-
mate heritability (So et al., 2011) and found that common variants
across the genome explained around 19% of the variance in hippocam-
pal volume, which is comparable to SNP-based estimates of heritability
formanypsychiatric disorders and other biological traits.More recently,
B.K. Bulik-Sullivan et al., 2015 introduced a similar method based on
linkage disequilibrium5 (LD) scores that is also able to recover heritabil-
ity from summary statistics. The LD score method assigns an LD score to
each SNP — the sum of its squared correlations (r2) with all other SNPs
in a 1 centimorgan window. One then regresses the chi-squared statis-
tics from a GWAS against the LD score for each SNP. The slope of the
resulting regression line depends on the sample size and the SNP-
heritability — the proportion of trait variance accounted for by all the
genotyped SNPs (see B. Bulik-Sullivan et al. (2015), B.K. Bulik-Sullivan
et al., 2015, for derivations).
A relatedmethod, GCTA (genome-wide complex trait analysis; Yang
et al., 2011) suggested that a still higher proportion of population
variance in brain volumetric measures may be accounted for based on
all genotyped SNPs, even in cases where we do not know which SNPs
help as predictors of the trait. Members of the ENIGMA Consortium
have applied this method to estimate SNP-based heritability for
structural (Toro et al., 2015) and functional (Dickie et al., 2014) brain
measures. Aworking group in ENIGMA, ENIGMA-GCTA, is now compar-
ing the GCTA and LD score methods to better estimate howmuch brain
variation is explainable by genotyped SNPs, at least for the brain mea-
sures that are most readily computed from MRI. SNP-based heritability
estimates of cortical surface area for different cortical subdivisions
calculated by GCTA were recently published (Chen et al., 2015). These
cortical subdivisions were deﬁned by a genetically based cortical
parcellation scheme (Chen et al., 2012).
The reason ENIGMA and other GWAS researchers are interested in
measuring heritability– and ideally the fraction of heritability explained
by common genetic variants – is that it should be possible to prioritize
brain measures for deeper genetic analysis based on their heritability,
reliability, polygenicity, and relevance to disease. Such rankings or
“Bayesian priors” would help in prioritizing research, making studies
more efﬁcient and better powered (Schork et al., 2013; Becker et al.,
submitted for publication; Holland et al., submitted for publication;
Wang et al., submitted for publication). Even so, there is no evidence
that phenotypes with higher heritability show stronger associations
with SNPs. One such example is white matter hyperintensities — a
brain measure with high heritability, for which speciﬁc genomic risk
factors have been hard to ﬁnd. The main beneﬁt of focusing on highly
heritable phenotypes comes from the fact that measurement error is
typically lower, and prioritizing brain measures is important as there
are so many ways to quantify brain structure and function.
A recurring caveat in this work is that the SNP effects are not
expected to be constant in all cohorts. They may depend on a person's
age, environment, or other circumstances. We now know from
ENIGMA2 that the top 8 loci associated with the volumes of subcortical
structures were detectable consistently worldwide, even though each
one accounts for b 1% of the variance. A later screen for age × SNP effects
suggested that some genes have a greater effect on brainmeasures later
in life (Hibar and the CHARGE and ENIGMA2 Consortia, submitted for
publication; Hibar et al., 2015a,b, in press), perhaps because they inter-
act adversely with other biological processes or environmental
stressors. In other words, although ENIGMA primarily uses meta-
analysis to assess evidence, we do not assume that the effect size is
always the same. Heterogeneity of effects is also assessed – a SNP effect
important late in life may not be replicated in younger samples.
Conversely, since most psychiatric disorders occur at a young age, one
may expect to ﬁnd associations that link genetic vulnerability, brain
structure and disease at a younger age, with effects that may diminish
later. Moreover, for certain disorders such as addiction, the psychologi-
cal, neurobiological and genetic factors most relevant at one age
4 Obviously the SNPs are “known” in the sense that they are on the genotyping chip. The
issue is that we do not know exactlywhich speciﬁc sets of SNPs or genes are truly contrib-
uting to a trait.
5 Linkage disequilibrium is the presence of statistical associations between alleles (ge-
nomic variants) at different loci in the genome, which arise because nearby regions on
the genome tend to be inherited together. Maps of the level of LD between adjacent SNPs
on the genome have been compiled for multiple ethnic groups. In imaging, LD leads to
peaks of association with brain measures, and these LD maps can be used analytically to
estimate SNP-basedmeasures of heritability or genetic correlations from GWAS summary
statistics.
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(e.g., impulsivity or sensation-seeking in adolescents experimenting
with drugs) may be quite different from the factors when dependent
(e.g., compulsivity or habit-based behavior) or when recovering
(e.g., stress regulation or cognitive control). Even so, ENIGMA's genomic
screens so far are only well-powered to detect SNP effects that are con-
sistent — there may also be SNP effects, so far undetected, that depend
on the demographics of the cohort assessed, or disease status, or other
circumstantial factors.
This is a reminder that predictive models work best in cohorts
similar to those where discoveries were made. Because of this concern,
which to some extent affects all brain imaging studies— and all human
studies — ENIGMA has diversiﬁed to over 33 countries. Recently,
ENIGMA partnered with other consortia such as the Japanese consor-
tium, COCORO (Okada et al., in press); encouragingly, effects of psychi-
atric illness on brain structural measures were replicated in Western
and Eastern populations, not just in the structures affected the most,
but in their rank order, showing congruence between independent
studies (van Erp et al., 2015; Okada et al., in press).
ENIGMA's Disease Studies
After the initial success of the genetic analyses (Stein et al., 2015;
Hibar and the CHARGE and ENIGMA2 Consortia, submitted for publica-
tion; Hibar et al., 2015a,b, in press), ENIGMA investigators had analyzed
brainMRI data fromwell over 30,000 individuals— around a third of the
data came from patients with a range of psychiatric conditions. In the
primary GWAS studies, analyses were run with and without patients,
and excluding patients did not affect the main ﬁndings; of course the
possibility remains that some SNP effects may be easier to detect in
some patient cohorts, but ENIGMA's overall results were not driven by
the presence of patients.
In 2012, ENIGMA formedworking groups on schizophrenia (van Erp
et al., 2015), bipolar disorder (Hibar and the CHARGE and ENIGMA2
Consortia, submitted for publication; Hibar et al., 2015a,b, in press),
major depression (Schmaal et al., 2015), and ADHD (Hoogman et al.,
2015); groups meta-analyzing data on 8 additional disorders have
been formed since, with current sample sizes detailed in Table 1; a
map of participating sites is shown in Fig. 2. In the summer of 2015, ad-
ditional working groups were formed on anorexia nervosa, recovery
after stroke, and Parkinson's disease — the current “roadmap” showing
relationships between ENIGMA's working groups is shown in Fig. 3
(also see http://enigma.ini.usc.edu for the latest status). The diseases
surveyed include many where controversy exists on the nature and
scope of disease effects on the brain. Given this controversy, the main
beneﬁt of meta-analysis is to discover which effects are strongest or
most reliably found, and which depend on known or unknown factors
of the cohorts assessed.
The initial goal of ENIGMA's Disease working groups has been to
meta-analyze effects of these disorders on the subcortical brain mea-
sures studied in the GWAS study. As scans had already been analyzed
with a harmonized protocol, and subtle genomic effects had been dis-
covered, there was some interest in ranking brain measures in terms
of disease effects (i.e., differences between patients and controls).
A secondary goal was to ﬁnd factors that mightmoderate how these
diseases impact the brain, such as a person's age, the duration or sever-
ity of illness, comorbidities, or treatment-related effects, such as which
medications the patients had been treated with, and for how long.
Clearly, treatment effects on the disease or the brain depend on many
factors. ENIGMA's multiple cohorts, in some cases, offered the opportu-
nity to gauge their generality or consistency. At the same time, many
groups joined ENIGMA and provided only brainmeasures as their initial
case–control analyses did not require genome-wide genotyping data on
their cohorts. As such, truly vast samples began to be analyzed (N =
8,927, in the published ENIGMA-Depression study; N = 10,194 in the
ENIGMA-Lifespan study; see Table 1).
At the time of writing, ENIGMA's ﬁrst studies of schizophrenia and
major depression have been published; results are compared in Fig. 4.
Some caveats are needed in showing these data side by side: the schizo-
phrenia andmajor depression patientswere not ascertained at the same
sites, so site or geographic effects may be present.
Among the subcortical structures so far assessed, the hippocampus
shows the greatest differences in each disorder in terms of statistical ef-
fect sizes— but inmajor depression, it is the only structure showing dif-
ferences, of those assessed so far (Schmaal et al., 2015). Many other
structures show volume deﬁcits or even hypertrophy in schizophrenia;
basal ganglia enlargement has been widely noted in prior studies of pa-
tients taking second-generation antipsychotics. In people with schizo-
phrenia, abnormal ventricular enlargement has long been reported (as
far back as Johnstone et al., 1976), but the natural variations in ventric-
ular size make the effect size smaller for this structure, even though the
absolute volume difference, on average, is greater than for other struc-
tures assessed. Inmajor depression, the hippocampal volume difference
was greater in patients who experiencedmore depressive episodes, and
in those diagnosed before the age of 21 years, whichwere at least partly
independent effects. This is in line with many prior reports of greater
brain differences in those with an earlier onset of the disease. Studies
of cortical measures are now underway across all ENIGMA disease
working groups;many cortical regions are commonly implicated in psy-
chiatric illness, so these analyses may offer a more complete picture re-
lating brain structural differences to clinical measures, medications, and
outcomes. At the same time, diffusion imaging studies are also under-
way; initial reports reveal consistent deﬁcits in fractional anisotropy –
a measure of white matter microstructure – for major white matter
tracts in schizophrenia (Bora et al., 2011; Holleran et al., 2014;
Ellison-Wright et al., 2014; Kelly et al., 2015); an interesting question
is whether antipsychotic medications affect white matter (Ahmed
et al., 2015) and brain connectivity (O'Donoghue et al., 2015) in a way
that ﬁts with their known effects on structural anatomy.
Extensions and Reﬁnements
Because of the worldwide scope of the ENIGMA studies, only
the brain measures that were most readily measured have so far been
examined. Clearly, there are measures that may be more relevant to
each disease or closer to the action of disease-causing genes, but
if they are difﬁcult to harmonize and measure in a standard way, the
available sample sizes will lag behind those available for the simpler
measures. Because of decades of work on shape analysis of anatomy,
several of the ENIGMA disease groups have begun to analyze and
meta-analyze subcortical shape (Gutman et al., 2015a,b,c), to map
the proﬁle of volumetric effects with more spatial precision. These
efforts will also determine whether shape metrics offer additional
predictive value over and above standard metrics, and in which
situations.
The ENIGMA-Laterality group is studying global trends in the proﬁle
of left–right differences in brain structure, and whether they relate to
handedness, sex, and disease status, in over 15,000 people (Guadalupe
et al., 2015, submitted for publication). Reduced or abnormal brain
asymmetry has been reported in many brain disorders (Okada et al.,
in press), but the scope and generality of these differences is not yet un-
derstood. Also, many important aspects of human brain function show
lateralization in terms of the underlying processing networks, but the
biology of this specialization is poorly understood, as are factors that in-
ﬂuence it. Whether brain asymmetry measures add value as diagnostic
predictors, will be testable across ENIGMA.
ENIGMA-EEG is studying the inﬂuence of genetic variants on brain
functional activity measured with scalp recorded electrical signals, in a
combined dataset from 10,155 individuals, ranging from 5 to 74 years
of age. EEGmetrics of brain functionmature rapidly with age, and relate
to aspects of cognition such as the brain's processing efﬁciency; they
also show abnormalities across many neurodevelopmental and
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psychiatric disorders. Combining data from several large twin and fam-
ily datasets, the ENIGMA-EEG working group is performing a genome-
wide association analysis of brain oscillatory power – a highly heritable
trait – before proceeding to in-depth analyses of lateralized activity,
brain connectivity, and network properties.
Brain-Wide Genome-Wide Association Studies
Voxel-based mapping methods are complementary to approaches
that measure the volumes of speciﬁc regions of the brain, and they
allow comprehensive and unbiased searches for effects of disease or ge-
netic variations across the brain. “Brain-wide” genome-wide searches,
Table 1
ENIGMA working groups, showing the number of independent participating samples, and the total sample size analyzed to date. A range of recruitment methods are represented. Some
ENIGMAworking groups, such as ENIGMA-Lifespan, ask questions that can be answered in healthy cohorts— often participants are controls from psychiatric studies, or population based
samples, inwhich peoplewith a current psychiatric diagnosismay be excluded altogether.Members of ENIGMAdiseaseworking groups have contributed their controls to several ongoing
studies, leading to normative samples of unprecedented size (over 10,000 in the Lifespan and 15,000 in the Lateralization groups). Some working groups study clinic-based samples of
cases and controls, and others study samples enriched for certain risk factors: over half of the people enrolled in ADNI, for example, have mild cognitive impairment, which puts them
at heightened risk for developing Alzheimer's disease. In ENIGMA-Lateralization, one participating cohort (BIL&GIN) enrolls left-handers at a higher frequency than found in the general
population, to boost power to understand handedness effects. Study designs, enrolment and sampling approaches vary widely across cohorts taking part in ENIGMA, so several ENIGMA
studies assess howmuch difference it makes to restrict or broaden analyses in certainways, such as pooling or separating certain categories of patients. Genetic analyses, for example, are
typically run twice, ﬁrst including patients and then excluding them. Disease group analyses may assess brain differences in different patient subgroups — chronically ill versus ﬁrst-
episode patients, at-risk siblings versus the general population, or people with different symptom proﬁles, or with distinct etiologies (e.g., negative symptoms, whose origin may differ
in schizophrenia, addiction, or PTSD). Abbreviations: SWEDD = scans without evidence of dopaminergic deﬁcit.
ENIGMA working groups Number of cohorts Total N (patient N) Age range (in years) Relevant publication(s)
ENIGMA2 GWAS (Subcortical) 50 30,717 (3,277 patients) 8–97 Hibar +287 authors, Nature, Jan. 2015
ENIGMA3 GWAS 50+ 32,000+ (4,000 patients) 8–97 In progress
ENIGMA DTI GWAS 35 13,500 (3,000 patients) neonates-90 (Kochunov et al., 2014, 2015 NIMG;
Jahanshad et al., 2013a,b NIMG)
ENIGMA EEG 4 10,155 (1,000 patients) 5–74 In preparation
ENIGMA-CNV 24 13,057 (1,800 patients) 13–90 In preparation
ENIGMA-Epigenetics 14 9,000 Across the lifespan In preparation
ENIGMA-Schizophrenia 26 7,308 (2,928 patients) average dataset age
ranges from 21 to 44
van Erp et al., 2015, Mol Psych.
ENIGMA-MDD (Major
depression)
20 10,105 (2,148 patients) 12–100 Schmaal et al., 2015, Mol Psych.
ENIGMA-BPD (Bipolar disorder) 20 4,304 (1,710 patients) 16–81 Hibar et al., in press, Mol Psych.
ENIGMA-ADHD 23 3,242 (1,713 patients) 4-63 Hoogman et al., OHBM, 2015, under
review Am J Psychiatry
ENIGMA-OCD 35 3,722 (1,935 patients) 6–65 In preparation
ENIGMA-Epilepsy 23 6,569 (3,800 patients) 18–55 In preparation
ENIGMA-PTSD 15 4,555 (1,050 patients) 8–67 In preparation
ENIGMA-Parkinson's 4 950 (626 Patients/SWEDD) 30–85 In preparation
ENIGMA-22q 22 1,020 (554 patients) 6–50 in preparation; Sun et al., SFN 2015
(abstract); Schneider et al., AJP, 2014;
Vorstman et al., JAMA Psych, 2015
ENIGMA-ASD (Autism Spectrum
Disorders)
20 1,960 (1,074 patients) 3–46 In preparation
ENIGMA-HIV 10 650 (all patients) 6–85 Fouche et al., OHBM, 2015; Nir et al.,
CNS, 2015
ENIGMA-Addictions 21 12,458 (3,820 patients) 7–68 Mackey et al., PBR, 2015
ENIGMA-GCTA 5 4,000+ 14–97 In preparation
Secondary Projects Number of cohorts Total N Age range (in years) Relevant publication(s)
ENIGMA-Lifespan 91 10,672 (healthy only) 2–92 Dima et al., 2015
Psychiatric cross-disorders 87 21,199 for 4 of the disorders (7,294 patients)
Schizophrenia: 4,568 (2,028 patients)
Bipolar Disorder: 4,358 (1,745 patients)
Major Depression: 9,031 (1,808 patients)
ADHD: 3,242 (1,713 patients)
4–100 –
ENIGMA-Lateralization 48 15,531 (0 patients) 8–90 Guadalupe et al., OHBM, 2015,
submitted for publication
ENIGMA-Plasticity 10 2,513 (2,153 healthy controls; 290
schizophrenia patients; 70 bipolar disorder
patients)
9-73 Brouwer et al., OHBM, 2015
ENIGMA-vGWAS meta-analysis 7 6,000 21–90 Jahanshad et al., OHBM, 2015, MICCAI
2015
ENIGMA-Schizophrenia-DTI 16 4,180 (1,927 patients) 18–60 Kelly et al., OHBM, 2015
ENIGMA-Schizophrenia-Relatives 8 4,079 (1,769 controls, 906 schizophrenia
patients, 1,404 relatives)
8–58 In preparation
ENIGMA-Schizophrenia-shape 2 462 (159 patients) 16–75 Gutman et al., OHBM, 2015; Gutman
et al., ISBI, 2015
ENIGMA-ILAE polygenic risk
collaboration
12 34,992 (8,835 patients) 18–70 Whelan et al., 2015
ENIGMA-MDD (Major
depression) DTI
15 2,100 (800 patients) 12–100 In preparation
ENIGMA-PGC Schizophrenia
Collaboration
PGC Schizophrenia and
ENIGMA2 summary
statistics
PGC-Schizophrenia GWAS was based on
36,989 patients and 113,075 controls
8–97 Franke et al., in press; Stein et al., 2015
ENIGMA–Connectome-Methods
harmonization
3 127 (healthy only) 21–85 de Reus et al., 2015
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or “voxelwise GWAS” (Shen et al., 2010; Stein et al., 2010a,b) can in-
volve over a trillion statistical tests. However, once we account for the
covariance within the image and genomic data, the number of
independent tests being conducted drops to less than 15,000 x
1,000,000. Given the extremely low p-values of some genetic associa-
tions in ENIGMA (p ~ 10−23 in Hibar and the CHARGE and ENIGMA2
Fig. 2. ENIGMAMap. The ENIGMA consortium now consists of over 30Working Groups made up of 500 scientists from over 200 institutions and 35 countries; several of these Working
Groups have several ongoing secondary projects, led by different investigators. Herewe show 12 of theworking groups, focusing on speciﬁc diseases andmethodologies, including ADHD,
autism, addiction, bipolar disorder, diffusion tensor imaging, epilepsy, HIV,major depressive disorder, OCD, PTSDand schizophrenia. Centerswhere individuals are scanned and genotyped
are denoted with color-coded pins (legend, bottom left).
Fig. 3. ENIGMARoadmap. The current organization of ENIGMA'sWorking Groups is shown here. Several groups relate brainmeasures to variation in the genome, and specialized groups
are dedicated to helping members run analyses of genome-wide SNP data, copy number variants, and epigenetic markers on the genome. In parallel, there are psychiatric and neurology
working groups dedicated to the study of worldwide data from a range of diseases. As shown here in detail for the schizophrenia working group, there are secondary projects, to relate
brain variation to speciﬁc symptoms or clinical measures. In parallel, support groups coordinate large scale efforts to harmonize DTI (diffusion tensor imaging) and related brain data
(Jahanshad et al., 2014). Partnerships between the DTI and Genomics groups are leading to genome-wide screens of DTI measures in over 13,000 people; cross-disorder partnerships
study brain features that may relate to diagnostic boundaries, or common co-morbidities, allowing factors driving brain variations to be disentangled.
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Consortia, submitted for publication; Hibar et al., 2015a,b, in press), sev-
eral effects can still survive a “double” Bonferroni correction for multi-
ple testing across both the image and the genome (Medland et al.,
2014).
As a result, several recent approaches have been developed to per-
form brain-wide genome-wide association studies to identify “spatial”
features associatedwith genetic variants, such as speciﬁcWMpathways
and their components, patterns of cortical thickness, or even activation
patterns, rather than “global” measures such as brain or subcortical
structure volumes. These approaches may be broadly divided into
(1) “brute force” methods, that use mass-univariate testing to test
every SNP for associations at each voxel in the image, and (2) data re-
ductionmethods, that attempt to reduce the search space by reducing
the number of features in the image, or the genome, or both (Vounou
et al., 2010, 2012; Ge et al., 2012). Data reduction methods may include
classical methods, such as canonical covariates analysis, or independent
components analysis (Gupta et al., 2015; Calhoun et al., 2015), or
modern variants such as sparse coding, compressive sensing, or “deep
learning” for feature discovery (see Thompson et al. (2013) for a review
of multivariate imaging genomics methods). Among the “brute force”
methods, Jahanshad et al. (2015a,b) detail a practical method whereby
several sites run a voxel-based morphometric analysis independently,
using a GWAS or other covariate-based analysis at each voxel, and
later communicate their ﬁndings to a central site for meta-analysis
(see Fig. 5). This approach was able to map out in the brain and meta-
analyze the effects of the top SNP from the ENIGMA2 study, which
screened the genome for variants associated with the size of subcortical
structures (Hibar and the CHARGE and ENIGMA2 Consortia, submitted
for publication; Hibar et al., 2015a,b, in press). To avoid re-computing
everything when a new site joins, this “meta-morphometry” approach
allows cohorts to align their data to their own brain templates, which
are later aligned to an overall mean template for meta-analysis. Such a
distributed effort offers many advantages for imaging genomics, due
to the vast number of predictors: as new cohorts join, each site's compu-
tational hardware can be leveraged by all the others. Such an approach
allows cooperative computation on data without requiring all the data
to be shared or ever transferred. This is an interesting area of coopera-
tivemachine learning that can also increase “buy-in” — opening up par-
ticipation to countries with stricter data transfer laws.
As part of ENIGMA3, a genome-wide screen of the cortex, one
subproject will adopt “genetic clustering”methods to identify coherent
patterns of gene effects in the brain (Chen et al., 2013, 2015). Based on
the notion of genetic correlation, brain regions or sets of voxels can be
grouped into clusters with similar genetic determination. The standard
decomposition of the brain into regions may be adapted to include
genetic clusters, or new regions where genome-wide association may
be more efﬁcient (Chiang et al., 2012). This approach has already been
applied to create genetic partitions of the cortex; initial work in
ENIGMA will overlay pre-made partitions on the cortical data from
each site. Genetic correlations can now be computed rapidly from
GWAS summary statistics (B. Bulik-Sullivan et al., 2015; B.K. Bulik-
Sullivan et al., 2015)making it feasible to compute and perform cluster-
ing on matrices of “genetic connectivity”whose entries are genetic cor-
relations. The ENIGMA-GCTA Working Group is currently studying
these methods, in multisite data.
Many disorders affect the brain's white matter and connectivity.
Using diffusion tensor imaging (DTI), ENIGMA's diseaseworking groups
have begun to compile evidence across cohorts for differences in a range
of DTI measures, which reﬂect white matter integrity and microstruc-
ture (Kelly et al., 2015). Several years of work went into harmonizing
ENIGMA's DTI analysis protocols, to studywhichmetrics are consistently
heritable and reproducible across multiple twin and family cohorts
worldwide (Jahanshad et al., 2013a,b; Kochunov 2014; Kochunov
et al., 2015). These DTI protocols have been carried forward into ongoing
GWAS and disease studies, and initial genome-wide screens of the
structural connectome (Jahanshad et al., 2013a,b; de Reus et al.,
2015). On the genetic side, ENIGMA working groups have also formed
to assess other kinds of genetic variation, including copy number
variants (CNVs), where abnormalities have been reported in autism,
schizophrenia, and learning disabilities. The ENIGMA CNV helpdesk is
now supervising supervising an initial analysis of CNV data in 13,057
people from 24 cohorts worldwide, after developing harmonized
protocols for CNV “calling” and quality control. Participating cohorts
include groups from Japan, Mexican-Americans, and people ofWestern
European, Nordic or Swedish ancestry. Initial efforts are evaluating
known “psychiatric” CNVs as predictors of MRI and DTI phenotypes
computed in other ENIGMA projects. Challenges include the pooling
of data from genotyping chips with different coverage; some have
sparse coverage of SNPs in regions with segmental duplications or
complex CNVs.
In a complementary initiative, the ENIGMA-Epigenetics working
group is studying epigenetic processes such as methylation, which is
an index of biological aging and lifecourse ‘stress’ that may explain an
important proportion of the gene-environment contribution to expres-
sion of many common diseases such as stroke and dementia. The group
is now performing epigenome-wide association studies (EWAS), across
Fig. 4. ENIGMA's studies of brain differences in disease revealed consistent patterns of subcortical volume differences across multiple cohorts with schizophrenia and major depression
(data reproduced, with permission, from van Erp et al., 2015; Schmaal et al., 2015, Molecular Psychiatry). Here we show the effect sizes (Cohen's d), for the mean volume difference
between patients and matched controls, for a range of brain structures measured fromMRI. After meta-analysis of all cohorts, in schizophrenia, a range of subcortical structures showed
volumetric differences, including hypertrophy, which may be due in part to antipsychotic treatment. Inmajor depression, the hippocampus is smaller in the depressed groups. Such data,
for these and other brainmeasures, is nowbeing compiled and analyzed across 12 disorders in ENIGMA(see Table 1 for a summary), andmay be useful for classiﬁcation, so long as relevant
confounds, site effects, and co-morbidities are appropriately modeled and understood.
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14 cohorts from Asia, Australia, North America, andWestern Europe, to
test associations between DNA methylation and brain measures,
initially focusing on total brain volume, subcortical volumes and cortical
thickness and surface areas. The working group is analyzing
methylation data from 9,000 people, of whom 5,000 have bothmethyl-
ation data andMRI. In addition, the ENIGMA-Epigenetics group is prior-
itizing the analysis of DNA methylation sites based on their effects on
gene expression or association with stress- and anxiety-related pheno-
types. There is some evidence of early life changes in stress response
genes through methylation (Backhouse et al., 2015), just as early life
events inﬂuence later life disease expression — notably stroke, white
matter hyperintensities, and cognitive impairment. Of great interest
are epigenetic changes throughout the life span, and with aging,
which may predict mortality from all causes, as well as physical and
cognitive performance. Associations are being tested ﬁrst for brain phe-
notypes that are known to change themost across the lifespan, based on
incoming information from ENIGMA's Lifespan study in over 10,000 in-
dividuals (Dima et al., 2015).
Relevance to Individual Evaluation, and Longitudinal Assessment
ENIGMA was not designed to make predictions about individuals
based on their scans and genomic data. As in most epidemiological
studies, the power lies in aggregating so much individual data that
subtle effects on the brain can be detected, including ﬁndings that
each cohort's datawere insufﬁcient to detect. In otherwords, its primary
goal has been to relate brain measures to disease and treatment effects,
and to variants in the genome. With the aggregated data, it has been
possible to determine how reproducible these patterns are worldwide.
Also, for the study of treatment effects, ENIGMA does not have the
ideal design. Ideally, onewould prefer to have pre–post treatment longi-
tudinal designs instead of the cross-sectional comparisons in ENIGMA,
where medication status is often confounded by age, disease duration,
comorbidity and disease severity.
Even if a large data sample is needed to discover a factor that inﬂu-
ences the brain, it does not mean that it is irrelevant to individuals;
APOE is one such example, discovered in 1993 by linkage analysis in
pedigrees. More recently, a rare variant in the TREM2 gene (Jonsson
et al., 2013; Rajagopalan et al., 2013) was found to affect Alzheimer's
disease risk and accelerate brain tissue loss as we age — perhaps
doubling loss rates in old age and increasing AD risk by a factor of 2–4.
This gene variant is undoubtedly important for those who carry it: it is
found in a little under 1% of controls and a little over 1% of AD patients.
How Does it Help to Predict Risk for Decline?
In current clinical practice, it is not recommended to notify a
research participant of their APOE status, andmost ethics boards clearly
deﬁne the circumstances inwhich incidentalﬁndings or health-relevant
information is communicated back to a research participant. In the case
of APOE, participants are not typically informed of their genetic status, as
there are no effective treatments for late–onset Alzheimer's disease.
Still, discovering predictors of more rapid decline is useful for the
pharmaceutical industry for understanding the behavior of participants
in clinical trials, and can greatly improve drug trial design, reducing
costs. Enrichment approaches use some characteristic of a patient to
select them for a clinical trial — this may be prior response to a certain
drug, or it also may be a prediction that they are more likely to decline
(FDA, 2013). In the AD ﬁeld, some clinical trials now select patients
based on having a PiB-positive PET scan (Ikonomovic et al., 2008) – as
evidence of incipient AD pathology – and the APOE4 risk genotype, as
carriers are more likely to develop AD. This selective enrolment allows
faster, less costly, and more well powered clinical trials, with demon-
strable reductions in the number of patients needed to show treatment
effects (Hua et al., submitted for publication).
ENIGMA's disease working groups are likely to broaden the set of
known factors that help predict recovery or decline. In ENIGMA-HIV,
for example, a key goal is to understand predictors of resilience —
factors that might forecast healthy brain development after the use of
antiretroviral treatment (Fouche et al., 2015). Crucially, it is important
Fig. 5. Meta-Analyzing Statistical Brain Maps. As in other ﬁelds of brainmapping, voxel-
based statistical analyses can map statistical associations between predictors and brain
signals. To meta-analyze maps of statistical associations across sites, Jahanshad et al.
(2015a,b,c) proposed a methodwhereby each site aligns data to their own brain template
(mean deformation template, orMDT). Statistics from each site aremeta-analyzed at each
voxel, after a second round of registration to an overall mean template (computed here
from 4 cohorts representing different parts of the lifespan). Analyses proceed in parallel,
using computational resources across all sites; analyses are updated when a new site
joins. This approach applies equally to voxel-based maps of function, and the ENIGMA-
Shape working group has modiﬁed it to work with surface-based coordinates (Gutman
et al., 2015a,b,c). If structural labels are used to drive the multi-channel registration (top
panels), in conjunctionwith anapproach suchas tensor-basedmorphometry, the resulting
local volumetricmeasures should closelymirror volumetric ﬁndings for speciﬁc regions of
interest. As such, some results of brain-wide genome-wide searches can be checked by
consulting genome-wide association results for speciﬁc regions of interest (Hibar et al.,
2015a,b; Adams and the CHARGE and ENIGMA2 Consortia, submitted for publication).
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to know if a predictor of decline is speciﬁc to one cohort or likely to
generalize to others, or if it is applicable in a limited set of situations.
Understanding how APOE4 and other major risk genes shift the lifetime
trajectory of brain measures will also help determine how much they
will help when used for clinical trial stratiﬁcation. This is a goal of the
ENIGMA-Lifespan group (Dima et al., 2015). Clearly, any predictors of
suicidal behavior would be very important in the management and
follow-up of patients with psychiatric disorders (Mathews et al.,
2013), and a secondary project on suicidality was started within the
ENIGMA-Depression working group (Rentería et al., submitted for
publication). Similarly, factors that predict whether ADHD in a child
will persist into adulthood, will have clinical utility (Hoogman et al.,
2015). Ultimately, the stratiﬁcation or clustering of ENIGMA cohort
data into subtypes, based on imaging, clinical or behavioral data, may
point to distinctions that help us understand the heterogeneity of
these disorders. This heterogeneity, without models to disentangle it,
makes individual patient predictions harder to make.
Normative Data Across the Human Lifespan
One effort where ENIGMA may contribute to individual prediction
and evaluation – albeit with some caveats – is the ENIGMA-Lifespan
project (Dima et al., 2015). In this work, ENIGMA cohorts are invited
to contribute volumetric measures from normal individuals in their
samples, which span the age range from 2 to 92 years of age. Although
some cohort studies focus on children or the elderly, many scan people
across the lifespan, allowing the computation of age-trajectories for sev-
eral key brainmeasures; the results show a remarkable difference in the
maturational trajectory of different structures, supporting many earlier
neurodevelopmental reports on the sequence of brain development
(Gogtay et al., 2004; Sowell et al., 2004). To cope with the non-
uniform sampling density of the cohorts, these overall trajectories
must be interpreted cautiously; clearly some parts of the lifespan are
better sampled than others, and unmodeled effects of scan site, demo-
graphics, and even cultural or environmental differences may drive
some of the effects. Clearly, disentangling the driving factors is statisti-
cally complex, but the potential is there, to derive normative measures
and models of our path through life, in cohort studies as diverse as
ENIGMA. The life span analyses (and normative curves) are also highly
relevant for neurodevelopmental disorders such as OCD, ADHD, autism,
etc. — for early detection, and secondary prevention in at-risk popula-
tions. Eventually, theremay even be efforts to train individuals in specif-
ic domains, to stimulate the maturation of speciﬁc brain areas that
appear to be deviant from the norm curves.
Such normative data have possible applications for individual
assessment, if used judiciously. In pediatrics, growth charts for height
and weight offer metrics of where a child stands relative to others of
the same age, as a Z-score for example. Similar metrics for brain struc-
ture, among others, may help in studies of neurodevelopment where
interventions and treatments are used to promote healthy maturation,
or recovery, as in the case of brain trauma, for example. Similarly, better
trajectories to chart loss of brain volume with advancing age help in
routine diagnosis of the individual with possible cognitive problems,
by indicating ﬁrst if their brain is within normal limits for age, and
secondly the precise centile on which it lies (Farrell et al., 2009; Dickie
et al., 2013, in press) – much more data is needed to populate these
graphs, but (much like child growth charts) they have the potential to
be highly valuable in routine clinical practice aswell as research.Original
scan data are being collected to expand these templates (e.g., www.
brainsimagebank.ac.uk).
Norming of brain measures also has commercial applications (Ochs
et al., 2015). ENIGMA relies heavily on developments in software for
imaging and genotype acquisition, quality control, and analysis, that
make standardized assessment possible. In some regions of the world,
such as Thailand and Cambodia, ENIGMA has contributors who are
interested in whether it makes sense to use brain development norms
from Western cohorts, or build their own (Jahanshad et al., 2015a,b,c;
Fouche et al., 2015). By comparing developmental trajectories across
very diverse multi-cohort data, better answers to these and other prac-
tical questions are within reach.
Machine Learning, Big Data, and Individual Prediction
With the advent of very large neuroimaging datasets, we can ﬁt
predictive models to the data and test them for their robustness. Our
models of how diseases and genes affect the brain are constantly
being tested and improved, especially in situations where statistical
effects have previously been too small to discover, or have been con-
founded by factors that cannot be adjusted for. In GWAS for example,
there are known genetic differences in allele frequencies across popula-
tions, and if these are not accurately modeled based on much larger
datasets, and adjusted for usingmultidimensional scaling, theywill con-
found the analysis and lead to spurious results - many more SNPs will
show “effects” on the brain, ultimately turning out to be false positives.
Years of “false alarms” (Farrell et al., 2015) led the genomics community
to adopt strict standards for reporting effects, including a standard
genome-wide signiﬁcance threshold (described above). In addition, in-
dependent replication of effects is required. In imaging, a somewhat
more ﬂexible approach has been used, with approaches from FDR to
random ﬁeld theory and permutation all co-existing in the literature;
the use of candidate brain regions or prior hypotheses in functional im-
aging studies is encouraged, but the use of candidate regions in geno-
mics is sometimes hotly debated as leading to many false positive
effects (Collins et al., 2012; Farrell et al., 2015; ENIGMA-DTI Working
Group, 2014). Munafò and Kempton (2014) argued that the growing
ﬂexibility in analyses used in neuroimaging is increasing the reporting
of false positive results, and meta-analyses may offer better estimates
of the validity of claims regarding brain differences in major depression
and bipolar illness, ﬁelds for which theymeta-analyzed the neuroimag-
ing literature.
Given the sample sizes attained, ENIGMA offers a framework not
only for unrestricted searches, but also to test more focused hypotheses
and provide internal replication using, for example, cross-validation
methods. So far, the Working Groups have over 30 “secondary pro-
posals”: many study clinical measures, disease subtypes, and patterns
of behavior such as suicidality or negative symptoms, or other differ-
ences that might contribute to the heterogeneity of brain disease and
outcomes. One such project, in the ENIGMA-Major Depression group,
assesses the effects of childhood trauma on depression-related brain
measures, a factor that may be modeled effectively by comparisons
with data from the ENIGMA-PTSD group, where childhood trauma is
also a major predictive factor. Partnerships between ENIGMA groups
may resolve some sources of brain differences that are difﬁcult to
disentangle. In HIV+ people who abuse stimulant drugs, for example,
white matter inﬂammation is commonly reported, while patterns of
accelerated atrophy are often seen in HIV+ people who do not use
intravenous drugs, especially in those carrying the APOE4 genotype.
These and other predictors can be assessed in partnerships between
the ENIGMA-Addictions and ENIGMA-HIV groups, by determining a
common core of predictor variables that can be harmonized.
More reﬁnedmodels are also needed: we now know that the proﬁle
and extent of brain differences in disease may depend critically on a
patient's age, duration of illness and course of treatment, as well as
adherence to the treatment, polypharmacy and other unmeasured
factors. Differences in ancestral background, as determined based on ge-
notype, are strongly related to systematic differences in brain shape
(Bakken et al., 2011; Fan et al., 2015). Any realistic understanding of
the brain imaging measures must take all these into account, as well
as acknowledge the existence of causal factors perhaps not yet known
or even imagined. The quest to identify individual predictors is there-
fore more likely to succeed in ﬁnding factors that affect aggregate risk
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and outcome in groups of individuals, rather than offer ﬁrm predictions
regarding an individual.
A more immediately achievable goal, for ENIGMA, is to rank brain
measures in terms of how well they do predict individual decline, or
diagnosis. Predictors of imminent brain decline are already used to
boost the power for clinical trials in Alzheimer's disease, by over-
enrolling, or separately analyzing patients whose brain measures, or
clinical and genomic measures, suggest that they will decline faster. In
ENIGMA, the ENIGMA-Plasticity group is evaluating the genetic
inﬂuences on measures of brain change, in a meta-analytic setting
(Brouwer et al., 2015). If reproducible drivers of brain decline could be
found by screening brain data worldwide, they would help in planning
enrichment approaches for drug trials. Several major initiatives have
this goal (e.g., ADNI; Jack et al., 2015). Currently, the only genetic
marker used for enrichment is APOE, but this may change asmore infor-
mation accumulates (see Lupton et al., submitted for publication). The
complex pattern of association between brain measures and SNPs
across the APOE gene (Hibar and the CHARGE and ENIGMA2 Consortia,
submitted for publication; Hibar et al., 2015a,b, in press) suggests that
future polygenic predictors based on machine learning may better pre-
dict clinical decline, and decline in brain measures, than the standard
APOE genetic test, which is based on just 2 SNPs.
Machine Learning
Innovations in machine learning make it possible to build robust
predictive models from millions of predictors, often using dimension
reduction techniques to home in on more efﬁcient sets of variables
that explain the most variance in the data; this vast ﬁeld, including
sparse learning and compressive sensing, is especially valuable in
imaging genomics, with millions of predictors in both the images and
the genome. Severalmachine learning developments have been applied
to connect genomic and imaging measures, using methods such as
parallel ICA (Gupta et al., 2015; Calhoun et al., 2015), elastic net (Wan
et al., 2011), sparse reduced rank regression (sRRR; Vounou et al.,
2010), among others. ENIGMA is beginning to test some of these
models, speciﬁcally in the disease working groups, for case-control
differentiation and differential diagnosis. Past efforts to combine
imaging and genomic data for outcome prediction suggest that imaging
measures may be much more predictive of future clinical decline than
genomic measures, but both are complementary (Peters and the
Alzheimer's Disease DREAM Challenge, submitted for publication).
Predictive models should improve as they draw on more data, and the
larger ENIGMA GWAS studies are now discovering more genetic
markers that can be used in predictive models for brain measures
(Hibar and the CHARGE and ENIGMA2Consortia, submitted for publica-
tion; Hibar et al., 2015a,b, in press; Adams and the CHARGE and ENIG-
MA2 Consortia, submitted for publication). However, compelling as
these approaches are and not wishing to dampen the enthusiasm for
these very promising techniques, the image measurements being pre-
dicted generally require a human check and correction if necessary, par-
ticularly in datasets with complex imaging features such as occur in
older patients with stroke – machine learning analysis algorithms still
cannot reliably separate the hyperintensity due to a small cortical
infarct from that due to a white matter hyperintensity or artifact,
reliably. Also, the variants driving the heritability of disease risk are
only just beginning to be discovered for many of the major brain
diseases studied within and outside of ENIGMA. Unsupervised learning
is also relevant for understanding the heterogeneity of diseases, which
has made it harder to discover their causes and mechanisms.
Brodersen et al. (2013) argued that one could use unsupervised learning
on imaging, clinical and genetic data to see whether subtypes (or
clusters) canbe identiﬁedwithin a disease, andwhether these data clus-
ter together in agreement (or disagreement) with current diagnostic
classiﬁcations.
In conclusion, we have reviewed current work by the ENIGMA
Consortium. ENIGMA began in 2009, and is now a distributed effort,
with over 30 working groups (see Table 1), coordinated from many
centers worldwide. As we noted, ENIGMA's main goals have been to
detect effects of disease and genetic variants on the brain, to see how
consistent these effects are worldwide, and to study what modulates
these effects. On the genetic side, it may soon be possible for polygenic
scoring to produce predictors that are routinely used in brain imaging
studies, explaining some of the observed variance. This may make
other effects easier to detect. On the disease side, we are beginning to
identify and conﬁrm distinctive patterns of brain differences in each of
a range of brain diseases, along with a better understanding of which
patterns are speciﬁc to given disorders, which patterns tend to general-
ize, and what factors account for the heterogeneity across cohorts. This
will help us understand the situations where predictive models can be
used, for diagnostic classiﬁcation, outcome prediction, and norming of
individual data against appropriate reference populations.
We end with a note in praise of small studies. Like any consortium,
ENIGMA would be impossible without the cohort studies and all the
individuals who contribute; most of the data analyzed in ENIGMA
came from cohorts with relatively modest sample sizes. Inevitably,
many hypotheses are not addressable on a large scale, and some
questions - especially causal questions - involve targeted interventions
or phenotypic assessments with a depth or sophistication not likely to
be attained at every site. As Aristotle said, “Nobody has the ability to
work everything out, but everyone has something useful to say;
working together, the whole vast world of science is within our
reach.” (ἐκ πάντων δὲ συναθροιζομένων γίγνεσθαί τι μέγεθος;
Aristotle,Metaphysics α, c. 350 BCE). This is the ENIGMA motto: http://
enigma.ini.usc.edu/about-2/.
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